Search the GHTC website

Global health R&D delivers for South Dakota

US government investment in global health R&D has delivered

$7.2 million
to South Dakota research institutions
South Dakota's top USG-funded global health R&D institutions

South Dakota's top USG-funded global health R&D institutions

South Dakota State University
$4.2 million
SAB Biotherapeutics
$2.8 million
Auratus Bio LLC
$269 thousand
Sterling Computers Corp.
$11 thousand

South Dakota's top areas of global health R&D by USG funding

Other coronaviruses (including MERS, SARS)
Diarrheal diseases
Flioviral diseases (including Ebola, Marburg)
Rheumatic fever
Global health R&D at work in South Dakota

Researchers at South Dakota State University are working to advance treatments for parasitic diseases, including leishmaniasis and sleeping sickness. The former, carried by sandflies, causes disfiguring skin lesions and in severe cases, deadly spleen and liver problems, and the latter, transmitted by the tsetse fly, leads to neurological and psychiatric issues. The research team has successfully isolated a molecule that naturally occurs in plants and has demonstrated antiparasitic properties. They are now working to modify and synthetically produce it as a potential drug for further testing. If successful, the work could lead to treatments for other parasitic infections, including Chagas disease.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: FDA/Michael J. Ermarth